Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Amgen has received approval to market palifermin. The drug is approved to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies undergoing chemotherapy, with or without radiation, followed by a bone marrow transplant.

Pharmacology Update: Palifermin Injection (KepivanceTM)